Salix Trumps Napo, Submits Crofelemer NDA for Review
One month after partner Napo Pharmaceuticals Inc. claimed to terminate their three-year-old collaboration to develop crofelemer for HIV-associated diarrhea, Salix Pharmaceuticals Ltd. plowed ahead by submitting a new drug application (NDA) for the drug to the FDA. The filing set in motion the 60-day clock for the FDA to conduct its review and determine whether to accept the NDA.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST